Potential Market Target small to mid-size medical device and diagnostics manufacturers who require CLIA waived drug screening tests, leveraging UCP Biosciences’s existing 15-test catalog and cGMP FDA-approved facility to offer scalable, compliant screening solutions.

Expansion Opportunities Explore partnerships with regional hospitals and clinics that previously purchased large test kits (as indicated by the 500-unit sale) to promote replenishment orders, bundled testing solutions, and recurring revenue through subscription or bulk discount programs.

Quality & Compliance Position the company’s FDA-approved cGMP manufacturing and ISO certification as a competitive edge to win bids for regulated environments, including contract manufacturing, white-labeling, and OEM arrangements with larger players.

Affordability & Accessibility Highlight rapid-result capability and ease of use to appeal to urgent-care centers, outpatient clinics, and point-of-care settings seeking quick, reliable drug screening with minimal training requirements.

Tech & Reach Leverage existing tech stack (WooCommerce and online presence) to drive direct-to-consumer and B2B e-commerce for test kits, while exploring digital marketing partnerships to expand geographic reach beyond San Jose to national or international buyers.